Sugi Predict

Sugi Predict / Compounds / SCHEMBL219172

SCHEMBL219172

SCHEMBL219172

Cn1c(Cl)cc(=O)n(C)c1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPK1 P28482 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ PLA2G7 Q13093 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221044 0.76 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL218257 0.76 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL28869790 0.76 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL219049 0.74 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3827955 0.74 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AMAPK1CYP1A2
SCHEMBL11401212 0.73 NQO2 (0.35) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL8830552 0.72 GSK3A (0.50) MEN1KMT2AMAPK1SMN1; SMN2HPGD
SCHEMBL1653731 0.72 ALDH1A1 (0.65) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL4796757 0.72 GRM2 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL91340 0.72 ALDH1A1 (0.45) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116874435-A Preparation method of urapidil intermediate impurity 1, 3-dimethyl-6- (propylamine) pyrimidine-2, 4-dione 河北广祥制药有限公司 2023-10-13 — — CN claimed
CN-109516960-B Preparation method of urapidil hydrochloride 河北一品制药股份有限公司 2021-07-02 — — CN claimed
CN-111646941-A Sulfonamide derivative and preparation method and application thereof 天津科技大学 2020-09-11 — — CN claimed
CN-109516960-A A method of new prepares Urapidil 河北品制药股份有限公司 2019-03-26 — — CN claimed
US-9458173-B2 Amides of 2-amino-4-arylthiazole compounds and their salts GLENMARK PHARMACEUTICALS S.A. (CH) 2016-10-04 — — US claimed
US-20150111038-A1 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-23 — — US claimed
EP-2858999-A2 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS Glenmark Pharmaceuticals S.A. (CH) 2015-04-15 — — EP claimed
WO-2013183035-A2 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-12-12 — — WO claimed
JP-59225170-A — — None — — JP disclosed
WO-2025245484-A1 FOXN1 ACTIVATORS THYMOFOX INC. (US) 2025-11-27 — — WO disclosed
CN-120040420-A Heterocyclic-pyrazole amine derivatives, preparation method thereof and application thereof in resisting tubercle bacillus infection 中国医学科学院医药生物技术研究所 2025-05-27 — — CN disclosed
US-20250066310-A1 MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Hangzhou Adamerck Pharmlabs Inc. (CN) 2025-02-27 — — US disclosed
EP-4458813-A1 MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Hangzhou Adamerck Pharmlabs Inc. (CN) 2024-11-06 — — EP disclosed
CN-116496234-B Preparation method of urapidil hydrochloride key intermediate 江苏润安制药有限公司 2024-09-13 — — CN disclosed
US-4460772-A IMMUNOASSAY MILES LABORATORIES, INC. (US) 1984-07-17 — — US disclosed
EP-0077896-A1 Theophylline derivatives, antibodies and their preparation from theophylline immunogens, as well as an immuno assay method and reagent means for determining theophylline MILES INC. (US) 1983-05-04 — — EP disclosed
EP-0037495-A1 Pyrimidyl quinazolines, process for their preparation and pharmaceutical compositions containing them CASSELLA Aktiengesellschaft (DE) 1981-10-14 — — EP disclosed
US-4216314-A CARDIOSELECTIVE B-ADRENOLYTIC AGENTS, ANTIARRHYTHMIC AGENTS AND HYPOTENSIVE AGENTS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DE) 1980-08-05 — — US disclosed
US-4067982-A LOWERING BLOOD PRESSURE, ANALGESIC, SEDATIVE, ANTIHISTAMINE Gulden, Byk (DT) 1978-01-10 — — US disclosed
US-3957786-A HYPOTENSIVE AGENTS BYK GULDEN (DT) 1976-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066310-A1 MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TYMP, UNG, UMPS ALDH1A1 82/4885MEN1 1546/4885KMT2A 3685/4885
US-20150111038-A1 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS AADAC, ABL2, ABL1 ALDH1A1 229/4885MEN1 3853/4885KMT2A 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.